# Auravax Therapeutics, Inc.

Canonical: https://abierto.us/vendors/auravax-therapeutics-inc-pan3zk2ylal2

- UEI: PAN3ZK2YLAL2
- CAGE: 969E2
- Location: Houston, TX
- Awards in window: 1 (4 transactions), $749,999 obligated, September 16, 2024 to December 19, 2025

## Awarding agencies

- Office of Assistant Secretary for Preparedness and Response: 1 awards, $749,999

## Industries

- 541714 Research and Development in Biotechnology (except Nanobiotechnology): $749,999

## Competition

- Full and Open Competition: 1 awards

## Largest awards

- 75A50124C00054 (definitive contract): $749,999, Barda - Aspr / Daappo / Barda DCMA. The Overall Objective of This Contract Is to Assess the Ability of Auravax Therapeutics? (Auravax) Novel Mucosal Adjuvant Nanosting-002, Together with Influenza Live Attenuated Virus (Lav) Created with Codagenix Novel Synthetic Attenuated Virus Engin. https://www.usaspending.gov/award/CONT_AWD_75A50124C00054_7505_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/auravax-therapeutics-inc-pan3zk2ylal2.